

CURRICULUM VITAE

Akram Miramin Mohammadi, MSc

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, 415 Taleghani Avenue, P.O. Box 14155-6383, Tehran 1416613675, Iran

Phone: (98-21) 8897 0657, mobile # 98 912145 9634

Faxphone: (98-21) 8897 0658/8895 3804

Email address: miramin48@yahoo.com

I. PERSONAL

A. Date and Place of Birth:

Present Home Address: No. 53, Salehian Alley, Shariati Street, Tehran, Iran

B. Married

C. Nationality: Iranian

D. Father's name: Seyed mohammad Miramin Mohammadi

E. Mother's name: Ehteram Mostafaie

II. EDUCATION

MSc. Department of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Major: Medical Mycology

BS: University of Tehran , Faculty of Sciences , Tehran, Iran

Major: Microbiology

III. ADDITIONAL TRAINING :

1. Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease University of Medical Sciences, Tehran, Medical Hall Complex Imam Khomeini , 1384
2. Workshop on EndNote, Organized by Center for Research and Training in Skin Disease and Leprosy Tehran University of Medical Science, 1389
3. Workshop on PCR Armin Teb Novin Company, 1389
4. Workshop on Real Time - PCR , Armin Teb Novin Company , 1389
5. Workshop on Evidence Base Medicine, Tehran University of Medical Science , 1389
6. Workshop on Scientific Writing, Tehran University of Medical Science, 1382
7. Workshop on ICDL, Tehran University of Medical Science , 1384
8. Workshop on Basic Molecular diagnosis & PCR techniques, Cinnagen Company , 1383

V. PROFESSIONAL EXPERIENCE

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Abstracts

Eskandari SE, Azimzadeh A, Bahar M, Safai Naraghi Z, Javadi A, Mohammadi A, Khamesipour A. The effect of microwave and/or infrared radiation in the treatment of Balb/c mice lesion induced by *L. major*. 4th World Congress on *Leishmaniasis*, Lucknow, India, 3-7 Feb 2009.

Nateghi-Rostami M, Khamesipour A, Keshavarz H, Eskandari SE, Mohammadi A. CD4⁺/CD8⁺ T cell responses to live or killed *Leishmania major* differently. 4th World Congress on *Leishmaniasis*, Lucknow, India, 3-7 February 2009.

Sohrabi Y., Jaafari MR., Mohammadi AM., Eskandari SE., Khamesipour A. Induction of Cell Mediated Immunity Against *Leishmaniasis* Using Mannan Coated Liposomes Encapsulated with Autoclaved *Leishmania major*. 12th Inter. Cong. of Immun. July 2004

Nateghi Rostami M., Keshavarz H., Khamesipour A., Mohammadi AM. Comparative analysis of the adjuvant activity of *Mycobacterium vaccae* and BCG mixed with Alum precipitated autoclaved *L. major* vaccine (Alum-ALM) in murine model of leishmaniasis. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sohrabi Y., Jaafari MR., **Miramin Mohammadi A.**, Eskandari SE., Javadi A., **Khamesipour A.** Evaluation of immune response induced by freeze/thawed thimerosal treated *L. major* (KLM) in murine model of *Leishmaniasis*. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sohrabi, Y., Jaafari, MR., **MirAmin-Mohammadi A.**, **Khamesipour A.**, Induction of cell mediated immunity against *Leishmaniasis* using mannan coated liposomes containing autoclaved *Leishmania major*. 6th International conference Liposome advances; progress in drug and vaccine delivery, 15-19 Dec., 2003, London, UK

Khamesipour A., Jaafari, MR., **MirAmin-Mohammadi A.**, Sohrabi, Y., Immunization of Balb/c mice with liposomes/autoclaved *Leishmania major* (ALM) composed of different phospholipids. 6th International conference Liposome advances; progress in drug and vaccine delivery, 15-19 Dec., 2003, London, UK

VII. PUBLICATIONS

1. **Mir Amin Mohammadi, A.**, Khamesipour, A., Khatami, A., Behnia, M., Eskandari, S.E. Cutaneous leishmaniasis in suspected patients referred to the Center for Research and Training in Skin diseases and Leprosy, Tehran, Iran from 2008 to 2011, Iranian Journal of Parasitology ,2013,8 (3), pp. 430-436
- 2.
3. Eskandari, S.E., Azimzadeh, A., Bahar, B., Naraghi, Z., Javadi, A, Khamesipour A, **Mohamadi M.** Efficacy of microwave and infrared radiation in the treatment of the skin lesions caused by leishmania major in an animal model. Iran J of Pub Health 2012, 41 (8) pp80-83.
4. Keshavarz Valian H., Nateghi Rostami M., Tasbihi M., **Miramin Mohammadi A.**, Eskandari S.E., Sarrafnejad A., Khamesipour A. CCR7 + Central and CCR7 - Effector Memory CD4 + T Cells in Human Cutaneous Leishmaniasis. Journal of Clinical Immunology 2012, Pages 1-15.
5. Khamesipour A., Nateghi Rostami M., Tasbihi M., **Miramin Mohammadi A.**, Shahrestani T., Sarrafnejad A., Sohrabi Y., Eskandaria SE., Keshavarz Valiane H. Phenotyping of circulating CD8⁺ T cell subsets in human cutaneous leishmaniasis. Microbes and Infection (2012) 14 (9) 702-711
6. Khamesipour A., Abbasi A., Firooz AR., **Mir Amin Mohammadi A.**, Eskandari SE., Jaafari MR., Treatment of Cutaneous Lesion of 20 Years' Duration Caused By Leishmanization,. 2012 Indian J. of Dermatology 2012 (7) 2:123-125.
7. Mahmoudi Rad M., **Miramin Mohammadi A.**, Tousi P., Khamesipour A., Ehsani A., Mirdamadi Y., Eskandari SE., Mahmoudi Rad N., Gerami Shoar M., Younespour Sh., Ghasem Z. Identification of *Malassezia* species associated with pityriasis versicolor using PCR-RFLP. Dermatology and Cosmetic 2011; 2 (2): 106-114 (Persian Language)
8. Nateghi Rostami M., Keshavarz H., Eskandari SE., **Miramin Mohammadi A.**, Shahrestani T., Sarrafnejad A., Khamesipour A., Differential in vitro CD4⁺/CD8⁺T-cell response to live vs. Killed *Leishmania major*. Parasite Immunology, 2010, 32, 101-110.

9. Nateghi Rostami M. Khamesipour A., Eskandari SE., **Miramin Mohammadi A .**, Sarraf Nejad A., Keshavarz H. Flow Cytometric Analysis of *Leishmania* Reactive CD4⁺/CD8⁺Lymphocyte Proliferation in Cutaneous *Leishmaniasis*. Iranian J Parasitol: Vol. 3, No.4, 2008, pp. 9-18.
10. JafariShakib R., Ajdary S., Mohtasham Amiri Z., **Miramin Mohammadi A.**, Nourijelyani K., Mortazavi H., Shokrgozar MA., Nikbin B., Khamesipour A., CD26 expression on CD4⁺ T cells in patients with cutaneous *Leishmaniasis*. Clinical Experimental Immunology 2008, 153: 31-36.
11. Kesharz Valian H., Khoshabe Abdollah Kenedy L., Nateghi Rostami M., **Miramin Mohammadi A.**, Khamesipour A., Role of Mycobacterium vaccae in the protection induced by first generation *Leishmania* vaccine against murine model of *Leishmaniasis*. Parasitology Research (2008) 103:21-28.
12. Sohrabi Y, Jaafari MR, **Mohammadi AM**, Eskandari SE, Khamesipour A. Evaluation of immune response against leishmaniasis in resistance C57 BL/6 mice immunized with liposomes containing autoclaved *Leishmania major* with BCG. Cell Mol Biol Lett 2005;10:98.
13. Nateghi Rostami M., Kesharz Valian H., **Mohammadi AM.**, **Khamesipour A.**, Evaluation of protection and immune response after vaccination with Alum-ALM mixed *Mycobacterium vaccae* or BCG in murine model. Iranian Journal of Dermatology 2005; 8(5):363-372 (Farsi Language).

XI. PROJECTS INVOLVED:

A. Co-investigator:

1. Double blind, randomized clinical trial on efficacy of combination of meglumine antimoniate (Glucantime) and topical nano-liposomal paromomycin for the treatment of anthroponotic cutaneous *Leishmaniasis* (ACL) caused by *Leishmania tropica*(Phase 3), funded by WHO/EMRO Proposal ID No SGS 10/69.
2. Double blind, randomized phase 3 efficacy trial of topical nano-liposomal paromomycin in the treatment of cutaneous *Leishmaniasis* caused by *L. major* (Phase 3), funded by, School of Pharmacy, Nanotechnology Research Center and Biotechnology Research Center, Mashhad University of Medical Sciences, P.O. Box 91775-1365, Mashhad, Iran and Zoonosis Control Unit, Diseases Management Center, MoH & ME and Center for Research and Training in Skin Diseases and Leprosy, P.O.Box 14155-6383, Tehran 14166, Iran
3. Pilot study of efficacy of topical nano-liposomal Glucantime for the treatment of cutaneous *Leishmaniasis* caused by *L. tropica*, supported by Mashhad University of Medical Sciences, Mashhad, Iran.
4. Pilot study of efficacy of topical nano-liposomal paromomycin for the treatment of cutaneous *Leishmaniasis* caused by *L. tropica*, supported by Mashhad University of Medical Sciences, Mashhad, Iran.
5. Study of T lymphocyte subsets in human *Leishmaniasis*, sponsored by School of Public Health and Institute of Public Health Research, Center for Research & Training

in Skin Diseases & Leprosy, Tehran University of Medical Sciences, 2007-present.

6. Characterization of Memory T Cells in Human *Leishmaniasis*, supported by Iran National Science Foundation, ID No 84112/23, 2007- present.

7. Evaluation of efficacy of intra-lesional injections of Glucantime once weekly in comparison with twice weekly in the treatment of acute Anthroponotic Cutaneous *Leishmaniasis* (ACL), CRTSDL, TUMS, 2007-2008.

8. Randomized open clinical trial on the efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous *Leishmaniasis* (ACL) caused by *L. tropica*. ID No. SGS05/97, EMRO/TDR. 2006-2008.

9. Phase II-b (safety & immunogenicity) of two doses of Alum-precipitated autoclaved *Leishmania major* (Alum-ALM) plus BCG in healthy volunteers with no response to leishmanin (LST=0), 2006-2008.

10. Phase II-b (safety & immunogenicity) of two doses of Alum-precipitated autoclaved *Leishmania major* (Alum-ALM) plus BCG in healthy volunteers with positive response to leishmanin (LST>0). 2006-2008.

11. Production, standardization, QC and preclinical testing of live *Leishmania major* as the basis for the establishment of a LZ platform. WHO/IVR. 2006-2008.

12. Leishmanization as live challenge for evaluation of candidate vaccine and protection against *Leishmaniasis*. TDR/WHO, ID NO. 980827.

13. Assess of possible induction of a Th1 response in mice immunized with *M. vaccae* mixed with killed *L. major*. Tehran University of Medical Sciences, undersecretary of Research

14. Immunization of susceptible (Balb/c) and resistant (C57BL/6) mice with different liposomes containing *Leishmania* antigens. Tehran University of Medical Sciences, undersecretary of Research

15. Evaluation of Th1/Th2 response using sCD26/sCD30 in cutaneous *Leishmaniasis*. Center for Research and Training in Skin Diseases and Leprosy, TUMS.

16. Evaluation of possible protection and immune response against *Leishmaniasis* induced by liposomes co-encapsulated with *Leishmania* Antigen and CpG ODNs in BALB/c mice. Center for Research and Training in Skin Diseases and Leprosy, TUMS.